Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
RXO has become a different stock since Monday. C.H. Robinson Worldwide agreed on October 5 to acquire the freight broker in an all-cash deal valued at $5.3 billion, and that single fact now dominates every data point in the snapshot.
The stock reflects the new reality. RXO closed at $28.54 on October 6, up 38% over the past month and 38% over the past week alone. That move is the deal premium doing its work. The stock had been trading in the high teens and low twenties for most of 2026. It is now converging toward the acquisition price, and the direction of travel is set by the merger terms rather than by freight fundamentals or quarterly earnings.
The most interesting tension in the positioning data is what the deal means for existing shorts. Short interest runs at 9.0% of the free float, roughly 14.8 million shares. With the stock now pricing close to deal value, the directional risk for shorts has flipped. In a cash merger, the acquirer sets the ceiling. Shorts can no longer profit from a move lower unless the deal breaks. The borrow market reflects none of that urgency yet: cost to borrow is just 0.46%, barely changed on the week, and availability is extremely loose at 536% of short interest, meaning shares to lend are plentiful relative to what is already borrowed. That combination of high short interest and easy, cheap borrow creates a slow-motion squeeze dynamic. Shorts face mark-to-market pain at today's price but face no mechanical squeeze from the lending market itself. The question for each short holder is whether they believe the deal closes, not whether they can afford to carry the position.
The analyst community has moved sharply in the past two days. JPMorgan upgraded from Underweight to Neutral and raised its target to $30, effectively a capitulation on a bearish view that has now been made redundant by the deal announcement. TD Cowen took the same step, upgrading from Sell to Hold and moving its target from $17.50 to $30.25 in a single action. Citigroup, Wells Fargo, and Truist Securities all raised targets to around $30. Jefferies moved in the opposite direction on the rating, downgrading from Buy to Hold at $30, a sensible adjustment given there is no longer a case for paying above the acquisition price. The consensus has effectively collapsed to one view: the deal defines the value, and any price above $30 is speculating on a bump or a competing bid. The mean analyst target of $26.83 reflects stale inputs from before the announcement and should be disregarded.
The ownership picture is central to the deal story. MFN Partners holds approximately 19.3% of RXO on a Schedule 13D filing, making it an activist holder with a disclosed position filed as recently as October 5. That filing, updating a stake first disclosed in February 2025, came the day the deal was announced. Orbis Investment Management carries another 22.1% on a passive 13G. Together, these two holders control well over 40% of the company. Both are named as sellers in the merger agreement. Their alignment behind the deal substantially reduces the risk of a shareholder vote failure. As the disclosure note requires: these stakes are as last disclosed around the 5% threshold and holders dropping below that level may not file again, but at these levels the directional intent is clear. BlackRock holds a further 14% on a passive 13G filed in February 2025.
RXO's next scheduled earnings date is November 6. That print will almost certainly be overshadowed by whatever stage the merger process has reached by then. The regulatory timeline, the shareholder vote date, and any competing offer are now the events worth tracking, not the freight rate environment or brokerage margin trends.
See the live data behind this article on ORTEX.
Open RXO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
